GlassScriptPhysician profile
Genesis Lee Young
NPI 1760851422
$8,829.94
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,787 · 2022: $5,285 · 2023: $1,758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,758.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,256.75 | 2021-2023 | Intellis Adaptivestim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $778.92 | 2021-2023 | Relistor |
| Si-Bone, INC. | $564.07 | 2021-2023 | |
| Collegium Pharmaceutical, INC. | $545.71 | 2021-2023 | Belbuca, Xtampza |
| Nevro Corp. | $476.92 | 2021-2023 | Senza |
| Abbvie INC. | $471.62 | 2021-2023 | |
| Protega Pharmaceutials INC | $325.80 | 2022-2023 | Roxybond |
| Idorsia Pharmaceuticals US INC | $232.31 | 2022-2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $219.11 | 2021-2023 | Ajovy, Austedo |
| Biodelivery Sciences International, INC. | $215.97 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $204.68 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $196.63 | 2022 | |
| Amgen INC. | $192.66 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $183.81 | 2021-2023 | Ztlido |
| Pfizer INC. | $155.43 | 2021-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $149.84 | 2021-2022 | |
| Grt US Holding, INC. | $109.39 | 2021-2022 | |
| Boston Scientific Corporation | $105.93 | 2021-2022 | |
| Eisai INC. | $71.40 | 2021 | |
| Hikma Pharmaceuticals USA | $66.41 | 2022 | |
| Allergan, INC. | $46.85 | 2021-2022 | |
| Tersera Therapeutics LLC | $41.19 | 2022-2023 | Prialt |
| Averitas Pharma INC. | $38.19 | 2023 | Qutenza |
| Lilly USA, LLC | $31.15 | 2021 | |
| Almatica Pharma LLC | $27.72 | 2023 | Gralise |
| Sanofi-Aventis U.S. LLC | $23.23 | 2023 | |
| Virtus Pharmaceuticals LLC | $19.55 | 2021 | |
| Merck Sharp & Dohme LLC | $18.76 | 2022 | |
| Arbor Pharmaceuticals, INC. | $17.33 | 2021 | |
| Horizon Therapeutics Plc | $15.83 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.88 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Genesis Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.